Literature DB >> 11102417

Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo.

H K Johansen1, T G Jensen, R B Dessau, B Lundgren, N Frimodt-Moller.   

Abstract

The combination of beta-lactam antibiotics and macrolides is often recommended for the initial empirical treatment of acute pneumonia in order to obtain activity against the most important pathogens. Theoretically, this combination may be inexpedient, as the bacteriostatic agent may antagonize the effect of the bactericidal agent. In this study, the possible interaction between penicillin and erythromycin was investigated in vitro and in vivo against four clinical isolates of Streptococcus pneumoniae with MICs of penicillin ranging from 0.016 to 0.5 mg/L and of erythromycin from 0. 25 to >128 mg/L. In vitro time-kill curves were generated with clinically relevant concentrations of penicillin (10 mg/L) and erythromycin (1 mg/L), either individually or in combination. Antagonism between penicillin and erythromycin was observed for the four isolates. In vivo interaction was investigated in the mouse peritonitis model. After intraperitoneal inoculation, penicillin and erythromycin were given either individually or in combination. For two of the four isolates, mortality was significantly higher in the groups treated with the combination of penicillin and erythromycin than in the groups treated with penicillin alone [32/36 (86%) vs. 3/12 (25%), P<0.05; and 24/36 (67%) vs. 3/12 (25%), P<0.05, respectively]. Using the mouse peritonitis model, in vivo time-kill curves showed that there was antagonism between erythromycin and penicillin for the examined isolate. The antagonism demonstrated in vitro and in vivo between penicillin and erythromycin suggests that ss-lactam antibiotics and macrolides should not be administered together unless pneumococcal infection is ruled out.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102417     DOI: 10.1093/jac/46.6.973

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo.

Authors:  Laura R Marks; G Iyer Parameswaran; Anders P Hakansson
Journal:  Infect Immun       Date:  2012-05-29       Impact factor: 3.441

2.  Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia.

Authors:  R Dwyer; A Ortqvist; E Aufwerber; B Henriques Normark; T J Marrie; M A Mufson; A Torres; M A Woodhead; M Alenius; M Kalin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

3.  Antibiotic efficacy is linked to bacterial cellular respiration.

Authors:  Michael A Lobritz; Peter Belenky; Caroline B M Porter; Arnaud Gutierrez; Jason H Yang; Eric G Schwarz; Daniel J Dwyer; Ahmad S Khalil; James J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

4.  Antagonism between bacteriostatic and bactericidal antibiotics is prevalent.

Authors:  Paolo S Ocampo; Viktória Lázár; Balázs Papp; Markus Arnoldini; Pia Abel zur Wiesch; Róbert Busa-Fekete; Gergely Fekete; Csaba Pál; Martin Ackermann; Sebastian Bonhoeffer
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 5.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment.

Authors:  Asher Brauner; Ofer Fridman; Orit Gefen; Nathalie Q Balaban
Journal:  Nat Rev Microbiol       Date:  2016-04       Impact factor: 60.633

6.  A novel initiation mechanism of death in Streptococcus pneumoniae induced by the human milk protein-lipid complex HAMLET and activated during physiological death.

Authors:  Emily A Clementi; Laura R Marks; Michael E Duffey; Anders P Hakansson
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

Review 7.  Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Authors:  Noa Eliakim-Raz; Eyal Robenshtok; Daphna Shefet; Anat Gafter-Gvili; Liat Vidal; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

8.  Association between antimicrobial drug class selection for treatment and retreatment of bovine respiratory disease and health, performance, and carcass quality outcomes in feedlot cattle.

Authors:  Johann F Coetzee; Natalia Cernicchiaro; Pritam K Sidhu; Michael D Kleinhenz
Journal:  J Anim Sci       Date:  2020-04-01       Impact factor: 3.159

Review 9.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

10.  Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing and outcomes.

Authors:  Wendy I Sligl; Holly Hoang; Dean T Eurich; Atul Malhotra; Thomas J Marrie; Sumit R Majumdar
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.